Checkpoint inhibitors: 'Raising the bar' also in brain metastases from non-small-cell lung cancer?

Sabrina Rossi, Giovanna Finocchiaro, Silvia Marchetti, Luca Toschi, Armando Santoro

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.

Original languageEnglish
Pages (from-to)403-410
Number of pages8
JournalImmunotherapy
Volume10
Issue number5
DOIs
Publication statusPublished - Apr 1 2018

Keywords

  • brain metastases NSCLC
  • checkpoint inhibitors blood-brain barrier
  • immunotherapy blood-brain barrier

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Checkpoint inhibitors: 'Raising the bar' also in brain metastases from non-small-cell lung cancer?'. Together they form a unique fingerprint.

Cite this